在帕金森病的临床前模型中基于格林的干预措施:系统性审查
Henrique José Cavalcanti Bezerra Gouveia1, Osmar Henrique Dos Santos-Júnior2, Johannes Frasnelli3
1Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC G8Z 4M3, Canada.
Brain research
|February 5, 2026
概括
在临床前模型中,格林及其激动剂通过保护神经元和改善运动和非运动症状来治疗帕金森病 (PD) 是有前途的.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 格林调节新陈代谢,饮食行为和神经保护.
- 帕金森病 (PD) 涉及多巴胺基神经元退化和改变的 ghrelin 水平.
- 格林林受体 (GHSR) 存在于黑质体中,这是PD中受到影响的关键区域.
研究的目的:
- 在实验性帕金森病模型中审查格林或GHSR激动剂的影响.
- 评估基于林的PD干预措施的治疗潜力.
主要方法:
- 在PubMed,Scopus,Web of Science和Embase的系统文献搜索.
- 分析了12项使用MPTP,6-OHDA和A53T转基因小鼠PD模型的研究.
- 用格林 (乙化/脱乙化) 和GHSR激动剂HM01.01进行干预的评估.
主要成果:
- 在PD模型中,格林林的使用减少了多巴胺基神经退行,并改善了PD模型中的运动功能.
- 格林对代谢和胃肠道功能产生了积极的影响,与非运动性PD症状相关.
- GHSR激动剂也表现出神经保护作用.
结论:
- 临床前证据表明,格林或GHSR激动剂对PD治疗有希望.
- 需要对渐进性PD模型进行进一步的研究,并考虑临床翻译的性别差异.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...


